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NANOMISEL FOSFOLIPID TERPEGILAT YANG MENGANDUNGI 
BUDESONID ATAU BEKLOMETASON DIPROPIONAT UNTUK 
PENYAMPAIAN PULMONARI 
ABSTRAK 
 
Tujuan kajian ini adalah untuk merumuskan dan menilaikan nanomisel yang 
mengandungi kortikosteroid yang tak-terlarutkan air, budesonid (BUD) atau 
beklometason dipropionat (BDP) untuk penyampaian pulmonari dengan 
menggunakan polimer- polimer terPEGilat (PEG5000-DSPE atau PEG2000-DSPE).  
 
Kesemua nanomisel fosfolipid yang terstabilkan secara sterik (SSMs) telah berjaya 
disediakan dengan menggunakan kaedah pemendakan mendakan bersama dan 
konstitusi semula. Rumusan SSM telah dicirikan dengan menggunakan kaedah 
fisikokimia yang berbeza. Terdapat perbezaan yang signifikan antara kecenderungan 
pemelarutan maksimum PEG5000-DSPE dan  PEG2000-DSPE  bagi BUD, iaitu lebih 
kurang 605.71±6.38 dan 646.27±4.93 µg/ml, masing-masing. Kecenderungan 
pemelarutan maksimum PEG5000-DSPE dan PEG2000-DSPE bagi BDP adalah lebih 
kurang 209.65±7.74 dan 210.01±5.28, masing-masing. Keputusan ini menunjukkan 
bahawa polimer terPEGilat mempunyai kecenderungan pemelarutan BUD yang lebih 
tinggi daripada BDP. Purata saiz partikel pada pemelarutan maksimum 
BUD:PEG2000-DSPE (15.97±1.91 nm) dan BDP:PEG2000-DSPE (15.44±1.66 nm) 
adalah lebih kecil daripada BUD:PEG5000-DSPE (20.45±1.65 nm)  dan  
BDP:PEG5000-DSPE (19.99±0.98 nm). SSMs PEG5000-DSPE tanpa drug telah berjaya 
diliofilkan pada kepekatan lebih kurang 5mM, manakala 10mM PEG2000-DSPE 
diperlukan untuk liofilisasi. Terdapat perbezaan yang tidak signifikan dalam saiz 
 xxxii
partikel, potensi zeta dan indeks polidispersiti di antara SSMs termuatkan drug dan 
SSM stanpa drug bagi polimer terPEGilat yang sama sebelum dan selepas proses 
liofilisasi. Peratusan hasil dan pemuatan drug bagi semua SSMs termuatkan drug 
adalah melebihi 95% dan 0.72%, masing-masing. Kedua-dua BUD dan BDP didapati 
berada dalam keadaan amorfus dengan DSC dan tidak bertindak balas secara kimia 
dengan polimer-polimer terPEGilat seperti yang ditunjukkan oleh spektrum FTIR. 
Pemeriksaan mikroskop elektron pemancaran (TEM) menunjukkan nanopartikel 
berbentuk sfera, sementara kajian mikroskop elektron imbasan (SEM) menunjukkan 
bentuk partikel BUD dan BDP yang berbeza berbanding dengan SSMs tanpa drug 
dan SSMs termuatkan drug yang terliofil. Kajian kestabilan jangka panjang dan 
jangka pendek menunjukkan bahawa SSMs termuatkan drug yang diliofilkan adalah 
stabil selama 1 tahun apabila disimpan pada suhu 4 ºC dan -20 ºC. 
 
Dua kaedah HPLC yang ringkas dan sensitif telah dibangunkan untuk menganalisis 
kepekatan BUD dan BDP dalam rumusan yang berbeza. Keputusan pencirian 
aerodinamik menunjukkan SSMs termuatkan drug adalah lebih baik daripada 
rumusan dagangan mikroampaian Pulmicort Respules® dan Clenil®. Tambahan lagi, 
kajian pelarutan in vitro menunjukkan pelepasan drug daripada SSMs yang lebih 
berpanjangan daripada produk rujukan yang setara. Perbandingan bagi kesan 
farmakodinamik di antara SSM termuatkan drug dan produk rujukan menunjukkan 
kelebihan SSM dalam mengurangkan bilangan sel-sel keseluruhan dan diferensial, 
dan memperbaiki perencatan sel inflamatori. Keputusan kajian ini telah 
menunjukkan potensi besar sistem pembawa nano yang telah dibangunkan untuk 
penyampaian kortikosteroid kepada tapak sasaran dalam rawatan asma dan penyakit 
inflamatori saluran pernafasan yang lain. 
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PEGYLATED PHOSPHOLIPID NANOMICELLES CONTAINING 
BUDESONIDE OR BECLOMETHASONE DIPROPIONATE FOR 
PULMONARY DELIVERY 
ABSTRACT 
 
The aims of the present study were to formulate and evaluate nanomicelles 
containing poorly water soluble corticosteroids, budesonide (BUD) or 
beclomethasone dipropionate (BDP) for pulmonary delivery using PEGylated 
polymers (PEG5000-DSPE and PEG2000-DSPE).  
 
All the sterically stabilized phospholipid nanomicelles (SSMs) were successfully 
prepared using a co-precipitation and reconstitution method. The SSMs were 
characterised by different physicochemical methods. There were significant 
differences between the maximum solubilisation tendencies of PEG5000-DSPE and 
PEG2000-DSPE for BUD, which were approximately 605.71±6.38 and 646.27±4.93 
µg/ml, respectively. The maximum solubilisation tendencies of PEG5000-DSPE and 
PEG2000-DSPE for BDP were approximately 209.65±7.74 and 210.01±5.28, 
respectively. These results showed that PEGylated polymers had greater tendencies 
to solubilise BUD than BDP. The mean particle sizes at maximum solubilisation of 
BUD:PEG2000-DSPE (15.97±1.91 nm) and BDP:PEG2000-DSPE (15.44±1.66 nm) 
were smaller than BUD:PEG5000-DSPE (20.45±1.65 nm) and BDP:PEG5000-DSPE 
(19.99±0.98 nm). Blank SSMs of PEG5000-DSPE were successfully lyophilised at a 
concentration of about 5 mM, while 10 mM of PEG2000-DSPE was needed for 
lyophilisation. There were insignificant differences in the particle size, zeta potential 
and polydispersity index between drug-loaded SSMs and blank SSMs of the same 
 xxxiv
PEGylated polymer before and after lyophilisation. The yield and drug loading 
percentages of all the drug-loaded SSMs were more than 95% and 0.72%, 
respectively. Both BUD and BDP were found to be amorphous by differential 
scanning calorimeter (DSC) and did not interact chemically with the PEGylated 
polymers as shown by Fourier transform infrared spectroscopy (FTIR). The 
transmission electron microscope (TEM) examination showed spherical 
nanoparticles, while the scanning electron microscope (SEM) investigation indicated 
that the shapes of the BUD and BDP particles were very different from the 
lyophilised blank and drug-loaded SSMs. Short- and long-term stability studies 
showed that the lyophilised drug-loaded SSMs were stable for 1 year when stored at 
both 4ºC and -20ºC. 
 
Two simple yet sensitive HPLC methods were developed in order to analyse the 
concentrations of BUD and BDP in different formulations. Aerodynamic 
characterisation of drug-loaded SSMs found that the SSMs were more superior than 
the marketed Pulmicort Respules® and Clenil® microsuspensions. In addition, the in 
vitro dissolution studies showed more prolonged drug release from the SSMs than 
their corresponding reference products. The pharmacodynamic study of drug-loaded 
SSMs showed the superiority of these formulations in reducing the total and 
differential cell counts and in enhancing the inhibition of inflammatory cells when 
compared with the reference products. The results of the present study indicated the 
great potential of the developed nanocarrier systems for the delivery of 
corticosteroids to the target sites for the treatment of asthma and other airway 
inflammatory diseases. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
 
1.1 Asthma 
Asthma is a chronic disorder of the conducting airway characterised by reversible 
narrowing of the airway due to inflammation and airflow obstruction that typically 
manifests itself as chest tightness, wheezing, cough and dyspnoea (Lemanske and 
Busse, 2003). The World Health Organization (WHO) estimates that about 150 
million people worldwide are affected by asthma (Johansson and Haahtela, 2004). 
Asthma is an allergic process in origin as more than 50% of adults and at least 80% 
of children with the disorder suffer from an allergy (Lemanske and Busse, 2003; 
Johansson and Haahtela, 2004).  
 
Inflammation in asthma involves many pathways that use various mechanisms or 
cells, cytokines and proinflammatory mediators. All these exert alterations in large 
and small airway structures, thickening the walls and producing excessive mucus and 
inflammatory exudates (Cerasoli, 2006). Different types of cells are involved in 
asthma pathogenesis, such as mast cells, eosinophils, basophils, neutrophils, 
macrophages, epithelial cells and lymphocytes, which contribute to ongoing airway 
inflammation through releasing a number of cytokines (Jarjour and Kelly, 2002). 
However, asthma is a heterogeneous disease with respect to immunopathology, 
clinical phenotypes, responses to therapies and natural history  (Holgate, 2008). 
 
Based on symptom frequency and severity, asthma can be classified into 4 
categories: mild intermittent, mild persistent, moderate persistent and severe 
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persistent (Lenfant and Taggart, 1999). To control this disease, pharmacotherapy 
treatment is the standard management in most asthmatic patients (Eid, 2004). This 
includes short-acting (albuterol) and long-acting (salmeterol) beta-agonists, inhaled 
corticosteroids (ICSs) (beclomethasone dipropionate (BDP), budesonide (BUD) and 
fluticasone), leukotriene modifier (montelukast), chromones (cromolyn sodium and 
nedocromil sodium), methylxantines (theophylline), anticholynergic antimuscarinic 
drugs (ipratropium bromide) and anti-IgE (omalizumab). Treatment options depend 
on the symptom frequency and severity provided by the National Asthma Education 
and Prevention Program (NAEPP) (Lenfant and Taggart, 1999; Eid, 2004) and the 
Global Initiative for Asthma (GINA) (Bateman et al., 2008).  
 
Among these medications, ICSs are the most efficient for treating asthma due to their 
potent effects on inflammatory cells (diminish inflammatory cell function and 
activation), as well as altering chemotaxis (specifically  neutrophils), impairing 
cytokine synthesis and release, reducing vascular leakage and mucus production, and 
increasing beta-adrenergic response (Szefler, 1991). 
 
Understanding the pathophysiology of asthma has demonstrated the important role of 
ICSs in the first-line therapy for asthmatic patients for decreasing the risk of 
mortality (Suissa et al., 2000). Different ICSs (alone or in combination with a beta-
agonist) with different devices are available to treat asthma and are approved by the 
Food and Drug Administration (FDA) (Table 1.1).  
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Table 1.1 ICSs with different devices for treating asthma. 
Model drug Brand name® Device 
Beclomethasone Dipropionate QVAR MDI* 
Budesonide Pulmicort Respules Microsuspension for nebulisation 
Budesonide Pulmicort Turbohaler DPI** 
Budesonide Pulmicort Flexhaler DPI 
Budesonide and formoterol 
fumarate 
Symbicort MDI 
Ciclesonide Alvesco MDI 
Fluticasone propionate Flovent HFA MDI 
Fluticasone propionate Flovent Diskus DPI 
Mometasone Asmanex DPI 
Fluticasone propionate and 
salmeterol xinafoate 
Advair HFA MDI 
Fluticasone propionate and 
salmeterol xinafoate 
Advair Diskus DPI 
* Metered Dose Inhaler; ** Dry Powder Inhaler 
 
 
1.2 Inhaled Corticosteroids to Treat Asthma  
Corticosteroids are not all equivalent due to the drug itself and/ or delivery device, 
which cause critical clinical differences in efficacy and safety (Allen et al., 2003). 
Figure 1.1 gives a basic understanding of the fates of the ICSs in the human body. 
 
Although ICSs are first line in treating persistent asthma, they lack a favourable 
reputation in terms of safety and tolerability due to local and systemic side effects 
(Table 1.2) (Hanania et al., 1995; Lipworth, 1999; Kelly and Nelson, 2003). These 
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side effects lead to low compliance or adherence to medications and, as a 
consequence, poor asthma control, thus significantly increasing asthma morbidity 
and mortality risks (Rossi et al., 2007). Therefore, different corticosteroids and 
devices have been developed to provide a higher therapeutic ratio with high potency, 
excellent efficacy, and optimum safety and tolerability, as shown in Table 1.1 
(Cerasoli, 2006). 
 
 
 
Figure 1.1 Fate of ICSs  (adapted from (Allen et al., 2003)). 
 
 
 
1.3 Pulmonary Drug Delivery System 
The local treatment of lung disorders such as asthma and chronic obstructive 
pulmonary disease (COPD) via pulmonary drug delivery offers many advantages 
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over oral or intravenous routes of administration as direct deposition of a drug at the 
diseased site increases local drug concentrations, improves the pulmonary receptor 
occupancy and reduces the overall dose required, therefore, reducing the side effects 
that result from high drug doses (Bailey and Berkland, 2009).  
 
 
Table 1.2 Local and systemic side effects of ICSs (Adapted from (Dahl, 2006)). 
Local side effects  Systemic side effects  
Pharyngitis HPA-axis suppression* 
Dysphonia 
Decrease in growth velocity and leg 
growth in children 
Reflex cough Decrease in bone mineral density 
Bronchospasm Bone fractures 
Oropharyngeal candidiasis Osteoporosis 
 
Skin thinning and bruising 
Cataracts and glaucoma 
* HPA , hypothalamic, pituitary, adrenal 
 
 
However, successful pulmonary delivery systems and clinical responses are affected 
by many factors including physiological and pathophysiological factors, delivery 
devices and corticosteroid pharmacokinetic/pharmacodynamic properties. 
 
1.3.1 Physiological and Pathophysiological Factors 
The respiratory system consists of the trachea, which divides into two bronchi. The 
bronchi branch into smaller bronchioles and finally the terminal bronchi, which end 
with the alveolar sac. Conducting airways are lined with ciliated epithelium and the 
lumen of the bronchiole is lined with serous fluid upon which floats a layer of 
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mucus. Cilia movement clears the mucous (mucociliary clearance) layer toward the 
proximal airways, where it is either swallowed or expectorated (Bailey and Berkland, 
2009). The alveoli are composed of non-ciliated epithelium and an extremely thin 
barrier between the pulmonary lumen and the blood capillaries for efficient mass 
transfer (Brain, 2007).  
 
Particle depositions in the lungs take place by inertial impaction, sedimentation or 
diffusion. Those with an aerodynamic diameter >10 µm are subjected to inertial 
impaction in the oropharyngeal region where they have little therapeutic effect, while 
particles with aerodynamic diameters of <1 µm mostly reach the alveolar region, but 
do not mostly deposit and are therefore exhaled. However, particles with 
aerodynamic diameters between 1 and 5 µm are efficiently deposited in the lung 
periphery to exert therapeutic effect (Musante et al., 2002; Sung et al., 2007). 
 
Once drug molecules deposit in the lungs, they either penetrate the mucus and 
become absorbed or are subjected to mucociliary clearance (Bailey and Berkland, 
2009). Mucociliary clearance in patients with acute asthma or COPD is markedly 
reduced and this clearance function is improved with the use of beta-agonists 
(Messina et al., 1991; Lindberg et al., 1995). The decrease in mucociliary clearance 
is compensated by cough clearance (Edsbäcker et al., 2008).  
 
Solubility of the inhaled drug particles and hence its pulmonary absorption may 
differ considerably between different drugs depending on their molecular weight, 
partition coefficient, hydrogen bond properties and polar surface (Tronde et al., 
2003a; Tronde et al., 2003b). After particles deposit on the surface of the airways, 
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they are wetted and dissolve into the airway lining fluid. Inhaled drug particles with 
low solubility take a substantial period of time for solubilisation and partitioning 
between the phases of the airway lining, and are preferentially cleared from the 
airways by mucociliary transport and phagocytosis. Inhaled drug particles with high 
solubility enter into and dissolve in the airway lining fluid more rapidly, and are 
therefore less susceptible to mucociliary clearance (John et al., 1994; Geiser et al., 
2000; Lay et al., 2003). 
 
In asthmatic patients, the systemic uptake of corticosteroid drugs also differs from 
that in healthy subjects, which depends on the severity of the disorder. For example, 
systemic uptake of fluticasone is lower in asthmatic patients than in healthy 
volunteers, while BUD systemic exposure has been shown to be higher than 
fluticasone in asthmatic patients and healthy volunteers (Harrison et al., 2001; 
Harrison and Tattersfield, 2003). These results have been confirmed by 
pharmacokinetic results following intravenous administration of fluticasone and 
BUD in healthy and asthmatic patients, which are identical for both groups (Brutsche 
et al., 2000; Thorsson et al., 2001). In addition, regional distribution of the inhaled 
corticosteroid differs substantially between healthy subjects and asthmatic or COPD 
patients where the airways are smaller or obstructed, which may lead to reduced 
therapeutic effect, given that most beneficial effects of a corticosteroid occur when it 
is evenly distributed throughout the lungs since inflammatory cells are present 
throughout the airways and alveolar tissue in asthma (Kraft et al., 1996; Carroll et 
al., 1997). Uneven distribution tends to impact the inhaled corticosteroid in the 
proximal parts of the lung that are subject to mucociliary clearance (Saari et al., 
1998). 
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1.3.2 Delivery Device 
There are three major types of inhalation devices used for pulmonary drug delivery: 
nebulisers, metered dose inhalers (MDIs) and dry powder inhalers (DPIs). From in 
vitro evaluation, each device has its own aerodynamic characteristics that may affect 
the clinical response (Sahib et al., 2010). The advantages and disadvantages of each 
system are summarised in Table 1.3.   
 
 
Table 1.3 Advantages and disadvantages of pulmonary delivery devices (adopted 
from (Labiris and Dolovich, 2003)). 
Inhalation 
device advantages disadvantages 
Nebulizers 
(jet, 
ultrasonic) 
No specific inhalation technique or co-
ordination required 
Aerosolizes most drug solutions 
Delivers large doses 
Suitable for infants and people too sick 
or physically unable to use other devices 
Time consuming 
Bulky 
Nonportable 
Contents easily contaminated 
Relatively expensive 
Poor delivery efficiency 
Drug wastage 
Wide performance variation between 
different models and operating 
conditions 
MDIs 
Compact 
Portable 
Multidose (approximately 200 doses) 
Inexpensive 
Sealed environment (no degradation of 
drug) 
Reproducible dosing 
Inhalation technique and patient co-
ordination required 
High oral deposition 
Maximum dose of 5 mg 
Limited range of drugs available 
DPIs 
Compact 
Portable 
Breath actuated 
Easy to use 
No hand-mouth co-ordination required 
Respirable dose dependent on 
inspiratory flow rate 
Humidity may cause powders to 
aggregate and capsules to soften 
Dose lost if patient inadvertently exhales 
into the DPI 
Most DPIs contain lactose 
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1.3.2.1 Nebulisers 
The important advantage of using nebulisers is the delivery of the therapeutic agents 
to infants and young children or geriatric patients, who often lack the coordination 
and/or ability to cooperate actively and achieve optimal delivery with the pressurised 
metered-dose or powder inhalers, and allows for inhalation during tidal breathing 
(Berg and Picard, 2009). However, most prescribed drugs using nebuliser delivery 
devices never reach the lungs and the majority of the drug is either retained within 
the nebuliser or released into the environment during expiration with an average of 
10% of the dose deposited in the lungs (O'Callaghan and Barry, 1997).  
 
From a clinical point of view, although jet nebulisers have  been  used  for  aerosol  
delivery  of water  soluble  compounds  and  micronised  suspensions (like Pulmicort 
Respules®), their  use with  hydrophobic  drugs  has  been  inadequate (Waldrep et 
al., 1997). Different nebulisers have different aerodynamic characteristics and 
therefore, give different therapeutic responses. Berg and Picard (2009) used thirty jet 
nebulisers to evaluate the aerodynamic characteristics of BUD and found different 
values. Moreover, Vaghi et al. (2005) showed the effect of formulation on the 
nebulisation characteristics of BUD (Pulmicort Respules®) and beclomethasone 
dipropionate (BDP) (Clenil® per Aerosol). In addition, suspension formulations are 
not nebulised as efficiently as solution formulations using ultrasound nebulisers 
(Nikander et al., 1999). Recently, advances in nebuliser development have improved 
nebuliser efficiency, such as the Pari LC nebuliser, which has been shown to have 
more efficient output than the Omron nebuliser (Smaldone et al., 1998; Berger, 
2009). Furthermore, to overcome drug wastage during exhalation, the Akita device 
(Activaero, Gemunden, Germany) allows individualised controlled inhalations in 
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combination with either a Pari jet nebuliser or an eFlow vibrating mesh, thus 
ensuring that the aerosol is delivered to the patient during inspiration only (Kesser 
and Geller, 2009). 
 
1.3.2.2 MDIs 
MDIs are common delivery devices used for inhalation because they are portable and 
inexpensive. Even though the dosing with MDIs is more reproducible than that with 
DPIs, they are generally more difficult to use because they need coordination 
between actuation and inhalation to ensure optimal drug deposition in the lungs 
(Cochrane et al., 2000). In addition, only 10 to 20% of the nominal dose of MDIs is 
deposited in the lungs due to large particle size and high speed spray that causes 
approximately 50 to 80% of the drug to be deposited in the oropharyngeal region 
(Newman et al., 1981). Different spacer devices and breath-actuated MDIs have been 
developed to eliminate coordination requirements. Using a spacer produces finer 
particles, but does not change the distribution of the aerosol in patients with airway 
obstructions, only decreasing particle deposition in the oropharyngeal region and 
increasing the dose delivered to the lungs (Dolovich et al., 1983; Newman and 
Newhouse, 1996; Kelly, 1998). Although breath-actuated MDIs increase the 
deposition of the therapeutic agent in the lungs, they do not decrease particle 
deposition in the oropharyngeal (Newman et al., 1991; Chapman et al., 1993; 
Cochrane et al., 2000). 
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1.3.2.3 DPIs 
These devices do not need coordination from the patients as they are breath-actuated 
and depend on the inspiratory flow rate, which can sometimes be difficult to replicate 
and tend to agglomerate due to electrostatic interactions and/or hygroscopic 
phenomena (Cochrane et al., 2000; Khilnani and Banga, 2008). Lung deposition is 
approximately 12 to 40% of the emitted dose with 20 to 25% of the drug being 
retained within the device (Pedersen, 1996; Dolovich, 1999). Although DPIs depend 
on the inspiratory flow rate (i.e., it is affected by patient status), it has been found 
that patients admitted to the emergency room can sufficiently create a drug aerosol 
that results in a good clinical effect. However, a lung deposition study of budesonide 
showed that when the inhalation flow decreased from 58 L/min to 36 L/min, the lung 
deposition of BUD decreased from around 28% to around 15% (Borgstrom et al., 
1994).  
 
1.3.3 Pharmacodynamic and Pharmacokinetic Properties of ICSs 
 
1.3.3.1 Pharmacodynamic Properties of ICSs 
The pharmacological effect of corticosteroids is mediated through the glucocorticoid 
receptor. Therefore, the receptor binding affinity determines the difference in 
potency of the different ICSs (Table 1.4), with a higher receptor affinity linked to a 
higher pharmacological response (Derendorf, 1997). The receptor binding affinities 
are measured relative to an affinity of 100 for the standard dexamethasone (Winkler 
et al., 2004). The potency of ICSs ranked in descending order is as follows: 
mometasone fuorate > fluticasone propionate > beclomethasone-17-monopropionate 
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> des-ciclesonide > budesonide > beclomethasone > beclomethasone dipropionate > 
ciclesonide. From a clinical point of view, receptor binding affinity can be 
compensated by administering dose equivalents. Therefore, the pharmacokinetic 
properties of the ICSs are the most important factors for evaluating their safety and 
efficacy (Allen et al., 2003). 
 
 
Table 1.4 Pharmacokinetic and pharmacodynamic parameter of ICSs (adapted from 
(Winkler et al., 2004)). 
ICSs RRA Foral  (%) Fu (%) CL (L/h) Vdss (L) t1/2 (h) 
Mometasone fuorate 2300 <1 1-2 54 - 5.8 
Fluticasone propionate 1800 <1 10 66-90 318-859 7-8 
Beclomethasone 
dipropionate 
53 15-20 13 150 20 0.5 
Beclomethasone-17- 
monopropionate 
1345 26 - 120 424 2.7 
Beclomethasone 76 - - - - - 
Ciclesonide 12 <1 <! 152 207 0.36 
Des-ciclesonide 1200 <1 <1 228 897 3.4 
Budesonide 935 11 12 84 183-301 2.8 
CL, Clearance; Foral , oral bioavailability; fu,  fraction unbound; RRA, relative receptor affinity; t1/2, 
half-life; Vdss, volume of distribution at steady state. 
 
 
1.3.3.2 Pharmacokinetic Properties 
Pharmacokinetics is a concentration-time relationship at the site of action. 
Pharmacokinetics properties of different ICSs are shown in Table 1.4. Some of the 
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ICSs are prodrugs, which are inactive compounds that are activated in the body after 
administration to exert their effects. Using prodrugs is beneficial due to reducing the 
risk of local as well as systemic side effects. For example, if an active corticosteroid 
is inhaled, some of the drug is deposited in the mouth and oropharynx, leading to 
side effects such as oral candidiasis, dysphonia and hoarseness. Inhaled prodrugs 
might reduce the incidence of local side effects in the mouth and oropharyngeal 
region due to the inactive drug form deposited there (Derendorf, 2007). Two ICSs 
are prodrugs, BDP and ciclesonide, which are activated to their active metabolite 
beclomethasone-17-monopropionate and des-ciclesonide, respectively (Freiwald et 
al., 2005; Derendorf, 2007). A clinical trial of ciclesonide showed a lower incidence 
of oropharyngeal adverse effects than fluticasone propionate (Kaliner, 2006). 
 
A large part of the inhaled drug (approximately 40 to 90%) is swallowed and 
available for systemic absorption. Oral bioavailability depends on the drug molecules 
as well as the delivery device. As only systemic absorption produces systemic side 
effects, it is desirable that oral bioavailability of ICSs be very low (Winkler et al., 
2004). For example, oral bioavailability of fluticasone propionate is less than 1% 
while that for 17-beclomethasone monopropionate is 26% (Thorsson et al., 1997; 
Daley Yates et al., 2001). 
 
In addition to oral bioavailability, all the drug that is deposited in the lungs is 
absorbed systemically (Allen et al., 2003). Delivery devices used for inhalation are 
an important factor for pulmonary bioavailability like the drug itself (Ben-Joseph, 
2000). For example, absolute bioavailability of fluticasone propionate with DPI has 
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been shown to be approximately 17%, while its bioavailability is around 26 to 29% 
with MDI (Mackie et al., 2000). 
 
Inhaled corticosteroid should be eliminated from systemic circulation in order to 
reduce systemic adverse effects. All ICSs are eliminated in the liver with values 
close to the liver blood flow. Therefore, development of new corticosteroids with 
high intrinsic hepatic clearance is unnecessary, since such steroids are not cleared 
more efficiently (Winkler et al., 2004). ICSs that are primarily present in tissues have 
large volumes of distribution, which suggests good penetration into the target tissues 
in the lungs and good pharmacodynamic activity (Allen et al., 2003). The volumes of 
distribution are correlated with the lipophilicity of the ICSs. The more lipophilic a 
corticosteroid is, the more it binds to the tissue, i.e., the higher the volume of 
distribution it will have (Winkler et al., 2004). 
 
Protein binding is also an important parameter because only free corticosteroid 
molecules can interact with corticosteroid receptors. Most ICSs have same protein 
binding percentage (10%), except for ciclesonide (1%). This causes ciclesonide to 
elicit much less cortisol suppression than other inhaled corticosteroids (Lipworth et 
al., 2005). The half-life parameter correlates to volume of distribution and clearance 
and is estimated after intravenous administration. However, the actual half-life of 
ICSs in the lungs depends on the pulmonary residence time (mean absorption time) 
and lipid conjugation. For example, the half-life of fluticasone propionate is between 
7 and 8 hours after intravenous administration and around 14 hours after inhalation 
and this is due to its low water solubility, thus leading to low absorption time and 
high availability in the lungs (Thorsson et al., 1997; Thorsson et al., 2001). While 
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lipid conjugation is pronounced with BUD, it forms reversible esters with fatty acids 
in the lungs and could increase the pulmonary half-life (Miller-Larsson et al., 1998).    
 
1.4 Nanotechnology for Pulmonary Delivery  
In pharmaceutical terms, a nanoparticle is defined as a particle with a size ranging 
from 1 or 10 to 1000 nm (Brigger et al., 2002; Sung et al., 2007; Gao et al., 2008; 
Kaur et al., 2008). However, particles larger than 200 nm are easily cleared from the 
circulation, given that spleen filtration captures particles exceeding 250 nm and liver 
filtration captures particles greater than 150 nm (Bawarski et al., 2008). Furthermore, 
capillaries of a tumour rarely exceed 300 nm in diameter (Moghimi et al., 2001) and 
those smaller than 260 nm can escape phagocytosis by macrophages (Yang et al., 
2008b). Therefore, current nanopharmaceutical formulations focus on particles 
smaller than 200 nm (Bawarski et al., 2008). The National Nanotechnology Initiative 
(NNI) defines nanotechnology as the study and use of structures in the size ranging 
from 1 to 100 nm (Zullo et al., 2002; Mishra et al., 2010).  
 
Nanocarriers have received a lot of attention in medical and drug formulations in 
recent years due to their advantages. They improve pharmacokinetics, minimise 
toxicity of therapeutic agents by their preferential accumulation at the target site 
(Alexis et al., 2008), increase the solubility of hydrophobic compounds and increase 
their stability (Hayama et al., 2008). They efficiently deliver therapeutic agents to the 
target organ due to their smaller size and higher barrier permeability (Wang et al., 
2002; Lukyanov et al., 2003). They are formulated from biodegradable materials, 
which decrease the possibilities of hypersensitivity reactions and affords good tissue 
compatibility (Panyam and Labhasetwar, 2003).  
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Nanocarriers for the pulmonary system is becoming a popular method to deliver 
therapeutic or diagnostic agents for local or systemic effects (Table 1.5) (Ely et al., 
2007; Azarmi et al., 2008). They offer many advantages that include:  
1. Achievement of relatively uniform distribution of drug dose through the 
lungs (Sung et al., 2007). 
2. Increase in the solubility of hydrophobic drugs and deposition in the fluid 
lining the lungs, which protects them from mucociliary clearance until their 
dissolution (Sung et al., 2007; Abdulla et al., 2010). 
3. Extended pharmacokinetic and pharmacodynamic of the inhaled drug in the 
airway system, which improve therapeutic management by reducing dose 
frequency and improving compliance, thus reducing side effects and cost 
(Saks and Gardner, 1997; Hardy and Chadwick, 2000). 
4. Suitability to deliver macromolecules and protect them from degradation 
(Zhang et al., 2001).  
5. Nanoparticles are more superior than microparticles in penetrating the airway 
sputum, which can improve the therapeutic efficacy of anti-asthmatic drugs 
(Lai et al., 2009; Suk et al., 2009). 
 
1.4.1 Nanocarrier Systems for Pulmonary Delivery  
 
1.4.1.1 Liposomes 
Liposomes are attractive candidates for pulmonary drug delivery vehicles, since they 
can be prepared from compounds endogenous to the lungs (such as lung surfactant) 
(Justo and Moraes, 2003). However, when liposomes are delivered to the lungs in the 
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liquid state, leakage of the encapsulated therapeutic agent occurs due to shearing 
forces (Leung et al., 1996). Therefore, liposomes in dry powder form are used to 
deliver agents to the lungs (Lu and Hickey, 2005; Chougule et al., 2007; Chougule et 
al., 2008; Changsan et al., 2009). Different therapeutic agents have been delivered to 
the lung using the liposomal formulation (Waldrep et al., 1997; Waldrep et al., 1998; 
Saari et al., 1999; Huang and Anderson, 2002; Bhavane et al., 2003; Wong et al., 
2003; Ohmori et al., 2005; Gagnadoux et al., 2008).  
 
1.4.1.2 Polymeric Nanoparticles 
The main advantages of polymeric nanoparticles in pulmonary drug delivery are in 
the control of drug release and protection of the therapeutic agent from degradation 
(Zhang et al., 2001; Bivas-Benita et al., 2004c; Zahoor et al., 2005; Ohashi et al., 
2009). Many biodegradable or biocompatible materials are used to prepare polymeric 
nanoparticles, such as poly(ε-caprolactone) (PCL), poly(lactic acid) (PLA), 
poly(lactic-co-glycolic acid) (PLGA), alginic acid, gelatin and chitosan (Mansour et 
al., 2009). However, long-term administration of these should be assessed as the 
degradation products of these polymers may affect the physiological function of 
respiratory surfactant in the alveoli, which in turn will affect pulmonary immunity 
control and adversely affect breathing. Toxicity and biodegradability of these 
polymers should also be closely examined for pulmonary delivery after repeat dosing 
(Mansour et al., 2009). Many examples of these formulations with different 
therapeutic agents are found in the literature (Rudolph et al., 2002; Pandey et al., 
2003; Zahoor et al., 2005; Azarmi et al., 2006; Li and Huang, 2006; Seong et al., 
2006; Yamamoto et al., 2007; Chono et al., 2008; Kimura et al., 2009; Ko et al., 
2009).   
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Table 1.5 Nanocarrier formulations for the pulmonary system. 
Therapeutic areas Model drugs References 
Local Sodium cromoglicate (Nolan et al., 2011) 
Local Beclomethasone Dipropionate (Jaafar-Maalej et al., 2011) 
Local Paclitaxel (Gill et al., 2011) 
Local Tacrolimus (Watts et al., 2011) 
Local Levofloxacin (Cheow et al., 2011) 
Local Doxorubicin  (Roa et al., 2011) 
Local Interfering RNA (siRNA) (Jensen et al., 2010) 
Local Diatrizoic acid (El-Gendy et al., 2010) 
Local 5-Fluorouracil (Kalantarian et al., 2010) 
Systemic Thymopentin (TP5) (Li et al., 2010) 
Local Rifampicin (Abdulla et al., 2010) 
Local Celecoxib (Patlolla et al., 2010) 
Local/systemic Itraconazole (Yang et al., 2010) 
Local Levofloxacin (Kho et al., 2010) 
Local Rifampicin (Saraogi et al., 2010) 
Local Cisplatin (Tseng et al., 2009) 
Local Paclitaxel (Hureaux et al., 2009) 
Local Paclitaxel (El-Gendy and Berkland, 2009) 
Local Tobramycin (Pilcer et al., 2009) 
Local/ systemic Nifedipine (Plumley et al., 2009) 
Local Budesonide (El Gendy et al., 2009) 
Local Ciprofloxacin (Zhao et al., 2009) 
Systemic Insulin (Liu et al., 2008) 
Systemic Insulin (Bailey et al., 2008) 
Local Pranlukast hemihydrate (Mizoe et al., 2007) 
Local Itraconazole (Alvarez et al., 2007) 
Local Doxorubicin  (Azarmi et al., 2006) 
Systemic Tetrahydrocannabinol (Van Drooge et al., 2005) 
Local Rifampicin; Isoniazid;  Pyrazinamide (Zahoor et al., 2005) 
Local Rifampicin; Isoniazid;  Pyrazinamide (Pandey and Khuller, 2005) 
Local Beclomethasone Dipropionate (Darwis and Kellaway, 2001) 
Local Ketotifen fumarate (Joshi and Misra, 2001) 
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1.4.1.3 Lipid Nanocarriers 
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) are a good 
example of nanocarrier systems for pulmonary delivery (Pandey and Khuller, 2005; 
Chattopadhyay et al., 2007; Liu et al., 2008; Patlolla et al., 2010).  SLN and NLC are 
made from solid lipids and solid lipids with spatially incompatible liquid lipids, 
respectively (Hu et al., 2005). These formulations are produced as alternatives to 
polymeric nanoparticles as they have a faster in vivo degradation and higher 
tolerability in the lungs compared to polymeric nanoparticles (Müller et al., 2000; 
Westesen, 2000; Liu et al., 2008; Doktorovová et al., 2010; Patlolla et al., 2010). 
Lipid nanocarriers are fully appreciated as pulmonary delivery systems only when 
they are formulated from physiological lipids, which have little or no cytotoxicity 
compared to polymer-based systems (Müller et al., 1997; Heydenreich et al., 2003).  
 
1.4.1.4 Submicron Emulsions and Suspension 
Aerosolisation of submicron emulsions or suspension as a liquid or dry powder form 
is an interesting way to deliver therapeutic agents (Bivas-Benita et al., 2004a; 
Shekunov et al., 2006; El-Gendy and Berkland, 2009; Amani et al., 2010; Cheow et 
al., 2011). However, more studies are required to assess the adverse effects of 
formula surfactants and oils on lung alveolar function (adverse interactions with lung 
surfactant) (Mansour et al., 2009). 
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1.5 Methods for Preparing Inhaled Formulations 
Many methods are used to prepare nanocarrier systems depending on the material 
that is used. However, there are two main processes to produce different inhaled 
therapeutic nanocarriers (Bailey and Berkland, 2009):  
 
1.5.1 Top-down Method 
In this method, large solid particles are mechanically broken down into smaller sizes. 
The most common method is wet milling and high pressure homogenisation (HPH) 
(Van Eerdenbrugh et al., 2008). Although they are scalable, reliable and capable of 
producing nanoparticles with narrow size distributions (Patravale et al., 2004), they 
have some disadvantages due to the mechanical nature. They are time and energy 
consuming because they need up to a few days to produce nanoparticles (Wiedmann 
et al., 1997; Ostrander et al., 1999; Tam et al., 2010). It is strongly suggested that 
these processes produce a high amorphous content of the model drug, which leads to 
long-term stability issues of the drug (Rabinow, 2004; Chow et al., 2007). In 
addition, there is a high chance for contamination from milling media or the 
homogeniser chamber (Patravale et al., 2004; Chow et al., 2007). Many therapeutic 
agents are formulated as a nanosystem using these methods found in the literature 
(Wiedmann et al., 1997; Ostrander et al., 1999; Jacobs and Müller, 2002; Rabinow, 
2004; James et al., 2008; Chiang et al., 2009; Shrewsbury et al., 2009; Yang et al., 
2010).  
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1.5.2 Bottom-up Method 
From the molecular level (dissolved drug), the nanoparticle can be formed with a 
better control of particle properties than the top-down method (Chow et al., 2007). 
 
1.5.2.1 Solvent Evaporation Method 
 
1.5.2.1.1 Spray Drying 
This method has been used efficiently to produce respirable colloidal systems 
(Freitas and Müller, 1998; Maa et al., 1998; Duddu et al., 2002; Stahl et al., 2002; 
Purvis et al., 2006; Mizoe et al., 2007; Yang et al., 2008e). It produces a dry powder 
in one step and allows the control of particle size and morphology by changing the 
experimental setup (Vehring, 2008). The solvent of the droplet is thermally removed 
and therefore cannot be used for heat sensitive drugs. In addition, it has an inefficient 
yield (Rogers et al., 2002). It is also used in the production of SLN (Freitas and 
Müller, 1998).  
 
1.5.2.1.2 Cryogenic Solvent Evaporation 
To overcome the problem of using heat in removing solvent in spray drying, a 
cryogenic solvent evaporation process can be used. It has a high and efficient yield 
reaching 95% compared to spray drying (Barron et al., 2003). It includes a droplet 
spraying into a cryogenic liquid and then lyophilising the frozen droplets. Different 
techniques use the principle of the cryogenic solvent evaporation process, which 
include spray freezing into liquid (SFL) (Rogers et al., 2002; Hu et al., 2004; 
Engstrom et al., 2008; Yang et al., 2008c), ultra rapid freezing (URF) (Sinswat et al., 
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2008; Yang et al., 2008c; Engstrom et al., 2009) and thin film freezing (TFF) 
(Engstrom et al., 2008; Engstrom et al., 2009).  
 
1.5.2.1.3 Evaporative Precipitation into Aqueous Solution (EPAS)  
EPAS is another solvent evaporation method (Hoeben et al., 2006; McConville et al., 
2006) where heated water is used instead of the cryogen as in SFL (Chen et al., 
2002). 
 
1.5.2.1.4 Microemulsion 
A nano- or microemulsion base can be used to trap the drug solution and 
subsequently remove the solvent under vacuum to produce a nanosuspension after 
rehydration or frozen and lyophilised or spray-freeze dried to produce dry 
nanoparticles. This method is commonly used to produce polymeric nanoparticles 
(Dailey et al., 2003a; Pandey et al., 2003; Bivas-Benita et al., 2004b; Cook et al., 
2005; Dailey et al., 2006; Shi et al., 2007).  
 
1.5.2.1.5 Condensation Aerosol Generation 
This process includes the condensation of a liquid or solid that is previously 
vaporised using a heated capillary by ambient air to form particulates suitable for 
inhalation (Gupta et al., 2003; Li et al., 2005). A few examples of this method can be 
found in the literature (Hong et al., 2002; Gupta et al., 2003; Li et al., 2005).  
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1.5.2.1.6 Rapid Expansion of Supercritical Solutions (RESS) 
Pre-heated supercritical fluid solution composed from CO2 and a model drug is 
ejected through a nozzle, resulting in solute precipitation due to the sudden drop in 
density and solubility power (Charpentier et al., 2008; Martín and Cocero, 2008; 
Pasquali et al., 2008). Carbon dioxide is usually used because it does not affect the 
environment when vented into the atmosphere (Snavely et al., 2002). 
 
1.5.2.2 Antisolvent Method 
This method involves the production of supersaturated solution from mixing the 
solution with an antisolvent that induces nucleation and simultaneous growth of 
nanoparticles by condensation and coagulation (Mehnert and Mäder, 2001; Dalvi and 
Dave, 2009). This includes the supercritical fluids process (gas antisolvent (GAS) or 
supercritical fluid antisolvent (SAS)), supercritical fluid extraction of emulsions 
(SFEE)) and the liquid antisolvent process (uses high gravity and sonication) 
(Chattopadhyay et al., 2006; Reverchon and Adami, 2006; Shekunov et al., 2006; 
Zhang et al., 2006b; Okamoto and Danjo, 2008; Pasquali and Bettini, 2008; Dhumal 
et al., 2009; Zhao et al., 2010). 
 
1.6 Polymeric Micelles 
In pharmaceutical technology, many drug-releasing and drug-targeting systems have 
been developed to reduce drug degradation and enhance the amount of drug in the 
target area (Jones and Leroux, 1999). In general, poor water-soluble agents are 
usually associated with poor absorption and bioavailability upon oral administration 
(Lipinski et al., 2001). In addition, from a pharmacological point of view, 
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hydrophobicity is beneficial for the drug–tissue relationship but formulation, 
solubilisation and stabilisation of these agents are problems that should be 
investigated (Sezgin et al., 2006). Accordingly, many pharmaceutical delivery 
systems from polymeric micelles have been introduced recently (Jones and Leroux, 
1999) due to their solubilising potential of poorly soluble drugs and the formation of 
small particle sizes (less than 100 nm) by which they evade phagocytosis (Kwon and 
Okano, 1996). 
 
Polymeric micelle so-called colloidal dispersions are self-assembled core-shell 
nanostructures formed in an aqueous solution consisting of hydrophobic fragments of 
amphiphilic molecules forming the core of a micelle, which is segregated from the 
environment by hydrophilic parts of the molecules that form the micelle corona (Gao 
et al., 2002; Riess, 2003). Cargo space (core) formed from the hydrophobic segment 
solubilises a variety of poorly soluble therapeutic and diagnostic agents. This 
solubilisation increases the bioavailability and circulation time after parenteral 
administration, as well as modifying the pharmacokinetics and biodistribution of the 
therapeutic agents (Jones and Leroux, 1999; Torchilin, 2001). The small size of the 
micelles permits their extravasation and accumulation in a variety of pathological 
sites such as tumours (Sezgin et al., 2006). Additionally, polymeric micelles are 
easily prepared on a large scale (Torchilin, 2001).  
 
Polymeric micelles are more stable than micelles prepared from conventional 
detergents and some amphiphilic co-polymers have critical micelle concentration 
(CMC) values as low as 10-6 M (Sung Bum et al., 1996; Kabanov et al., 2002). This 
is especially important from a practical point of view, since upon dilution with a 
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large volume of biological fluid, micelles with a high CMC value may dissociate into 
monomers and their content may precipitate (Torchilin, 2004). Moreover, polymeric 
micelles have high kinetic stability due to the presence of multiple sites capable of 
mediating the hydrophobic interaction between each other and/or hydrophobic drugs 
(Yokoyama et al., 1993). 
 
The major driving force behind self-association of amphiphilic polymers is the 
decrease in free energy of the system due to the removal of a hydrophobic segment 
from the surrounding aqueous media with the formation of a micelle cargo space 
stabilised with hydrophilic blocks exposed to water (Kwon and Okano, 1999). The 
properties of the core and corona of the polymeric micelles give the characteristic 
behaviour in the biological system (Gref et al., 1995; Cammas et al., 1997; Kuntz 
and Mark Saltzman, 1997; Inoue et al., 1998). Different polymeric micelle 
copolymers (but not restricted) have been investigated (Table 1.6) to solubilise and 
target many poorly soluble compounds. An important type of polymeric micelle is 
phospholipid micelles, which are sterically stabilised phospholipid nanomicelles 
(SSMs) composed of polyethylene glycol and phospholipids (PEGylated 
phospholipids). 
 
1.7 PEGylated Phospholipid Micelles 
PEGylated phospholipids are similar to the amphiphilic copolymers of the A-B type, 
except that the hydrophobic part is a lipid instead of a hydrophobic polymer block. 
Acyl chains of lipids form the cargo space of the polymeric micelles that encapsulate 
or solubilise a variety of poorly soluble therapeutic and diagnostic agents (Lukyanov 
and Torchilin, 2004). One of the most important PEGylated phospholipid is 
